Effect sizes and 95% CI for measures of pain in analyses by protocol.
| Variables | Unadjusted Analyses, n = 32 | Adjusted Analyses, n = 32 | ||||
|---|---|---|---|---|---|---|
| Change during Placebo | Change during Milnacipran | Difference between Placebo and Milnacipran | Change during Placebo | Change during Milnacipran Placebo | Difference between and Milnacipran | |
| BPI-sf Pain* | −0.25 (−0.95 to 0.45) | −0.72 (−1.33 to −0.11) | −0.47 (−1.45 to 0.51) | −0.28 (−0.90 to 0.35) | −0.67 (−1.29 to −0.04) | −0.39 (−1.27 to 0.49) |
| SIS** | −0.80 (−1.48 to −0.11) | −0.73 (−1.31 to −0.16) | 0.06 (−0.90 to 1.03) | −0.80 (−1.43 to −0.17) | −0.71 (−1.33 to −0.07) | 0.10 (−0.80 to 0.99) |
| Thumbnail PPT† | 0.08 (−0.52 to 0.67) | 0.76 (0.25–1.27) | 0.69 (0.04–1.34) | 0.08 (−0.49 to 0.64) | 0.75 (0.19–1.31) | 0.67 (0.02–1.32) |
| Trapezius PPT† | 0.69 (0.13–1.26) | 0.35 (−0.18 to 0.88) | −0.34 (−1.04 to 0.36) | 0.71 (0.16 to 1.26) | 0.33 (−0.22 to 0.88) | −0.38 (−1.06 to 0.31) |
| Wrist PPT† | 0.81 (0.23–1.39) | 0.77 (0.19–1.36) | 0.04 (−0.68 to 0.76) | 0.75 (0.17–1.33) | 0.79 (0.21–1.37) | 0.04 (−0.69 to 0.78) |
| Knee PPT† | 0.21 (−0.47 to 0.90) | 0.37 (−0.16 to 0.90) | 0.16 (−0.64 to 0.95) | 0.20 (−0.42 to 0.83) | 0.37 (−0.26 to 0.99) | 0.16 (−0.64 to 0.97) |
| CPM† | 0.17 (−0.26 to 0.59) | 0.09 (−0.54 to 0.71) | −0.08 (−0.88 to 0.72) | 0.17 (−0.37 to 0.71) | 0.09 (−0.45 to 0.64) | −0.07 (−0.84 to 0.69) |
Significant data are in bold face.
↵* Based on a 0–10 scale with 10 being worse pain.
↵** Based on 0–9.75 scale with 9.75 being greater intensity of symptoms consistent with fibromyalgia.
↵† Units are kg/cm2. BPI-sf: Brief Pain Inventory short form; SIS: Symptom Intensity Scale; PPT: pressure pain threshold; CPM: conditioned pain modulation.